Previous 10 | Next 10 |
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire -- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses o...
-- Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to ...
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma PR Newswire -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading...
Arcellx press release ( NASDAQ: ACLX ): Q3 GAAP EPS of -$2.12. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months. For further details ...
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress PR Newswire -- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 6...
The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow
Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...
Summary Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts. Data shared in June for CART-ddBCMA in r/r multiple myeloma show...
Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology. This data will be out sometime next year. I covered Arcellx ( ACLX ) at its IPO in January. Arcellx is a clinical stage biopharma developing cancer immunothera...
Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million For further details see: Arcellx GAAP EPS of -$0.88
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...